140
Participants
Start Date
January 30, 2023
Primary Completion Date
January 30, 2028
Study Completion Date
January 30, 2028
Adaptive Aerobic Training/AT Dosing
o In Phase A (\~32 weeks), AT will consist of supervised walking delivered up to 7 days per week using an adaptive dosing schedule that starts at 90 min/wk and is escalated 30 min/wk every 2 weeks to a maximal dose of 300 mins/wk. In Phase B (\~20 weeks), AT will consist of supervised adaptive AT dosing in patients with a CRF Δ\<3.50 ml O2 .kg-1.min-1 from baseline to \~32 weeks, or unsupervised AT in patients with a CRF Δ\>3.50 ml O2 .kg-1.min-1 from baseline to \~32 weeks. Supervised AT will be monitored using TeleEx.
Standard (fixed) Aerobic Training/AT dosing
In Phase A (\~32 weeks), AT will consist of supervised walking delivered up to 7 days per week to achieve a cumulative total duration of: 90 min/wk (standard fixed dosing). In Phase B (\~20 weeks), AT will consist of supervised adaptive AT dosing in patients with a CRF Δ\<3.50 ml O2 .kg-1.min-1 from baseline to \~32 weeks, or unsupervised AT in patients with a CRF Δ\>3.50 ml O2 .kg-1.min-1 from baseline to \~32 weeks. Supervised AT will be monitored using TeleEx.
RECRUITING
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
RECRUITING
Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
RECRUITING
Memorial Sloan Kettering Nassau (Limited protocol activities), Rockville Centre
RECRUITING
Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack
RECRUITING
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge
RECRUITING
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown
RECRUITING
Memorial Sloan Kettering Bergen (Limited protocol activities), Montvale
Memorial Sloan Kettering Cancer Center
OTHER